Emerging biopharma companies (EBPs) have steadily expanded their role as key drivers of biomedical innovation. Over the past decade, these companies have increasingly held on to their products to file and commercialise their assets themselves.

For most EBPs, the US market is the natural first priority for their own commercialisation efforts. However, to maximise the value of their products, EBPs should expand their horizons beyond the US. Europe, as the second largest pharmaceutical market after the US, is the obvious next choice.

In this white paper, we will explore opportunities and challenges for EBPs commercialising in Europe and the key choices these companies have to make to succeed.